Search Results - "RHIEM, K"

Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto by Loibl, S., Weber, K.E., Timms, K.M., Elkin, E.P., Hahnen, E., Fasching, P.A., Lederer, B., Denkert, C., Schneeweiss, A., Braun, S., Salat, C.T., Rezai, M., Blohmer, J.U., Zahm, D.M., Jackisch, C., Gerber, B., Klare, P., Kümmel, S., Schem, C., Paepke, S., Schmutzler, R., Rhiem, K., Penn, S., Reid, J., Nekljudova, V., Hartman, A.-R., von Minckwitz, G., Untch, M.

“…In the neoadjuvant GeparSixto study, adding carboplatin to taxane- and anthracycline-based chemotherapy improved pathological complete response (pCR) rates in…”
Get full text

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study by Loibl, S., Untch, M., Burchardi, N., Huober, J., Sinn, B.V., Blohmer, J.-U., Grischke, E.-M., Furlanetto, J., Tesch, H., Hanusch, C., Engels, K., Rezai, M., Jackisch, C., Schmitt, W.D., von Minckwitz, G., Thomalla, J., Kümmel, S., Rautenberg, B., Fasching, P.A., Weber, K., Rhiem, K., Denkert, C., Schneeweiss, A.

“…Combining immune-checkpoint inhibitors with chemotherapy yielded an increased response rates in patients with metastatic triple-negative breast cancer (TNBC)…”
Get full text

Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response by Loibl, S., Schneeweiss, A., Huober, J., Braun, M., Rey, J., Blohmer, J.-U., Furlanetto, J., Zahm, D.-M., Hanusch, C., Thomalla, J., Jackisch, C., Staib, P., Link, T., Rhiem, K., Solbach, C., Fasching, P.A., Nekljudova, V., Denkert, C., Untch, M.

“…Addition of immune checkpoint inhibitors to neoadjuvant chemotherapy (NACT) is a promising strategy in early breast cancer, but the optimal duration of therapy…”
Get full text

Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study) by Fasching, P.A., Link, T., Hauke, J., Seither, F., Jackisch, C., Klare, P., Schmatloch, S., Hanusch, C., Huober, J., Stefek, A., Seiler, S., Schmitt, W.D., Uleer, C., Doering, G., Rhiem, K., Schneeweiss, A., Engels, K., Denkert, C., Schmutzler, R.K., Hahnen, E., Untch, M., Burchardi, N., Blohmer, J.-U., Loibl, S.

“…The efficacy and toxicity of olaparib as combination therapy in early breast cancer (BC) patients with homologous recombinant deficiency (HRD) [score high…”
Get full text

Phenotype analysis of families with TP53 germline variants at the Center for Familial Breast and Ovarian Cancer, Cologne by Kast, K., Rhiem, K., Larsen, M., Wappenschmidt, B., Schmutzler, R.

“…Purpose Tumor protein p53 (TP53) pathogenic variant (PV) carriers are identified during genetic testing for hereditary causes of cancer. PVs in TP53 are…”
Get full text

Predictors of cardiopulmonary fitness in cancer-affected and -unaffected women with a pathogenic germline variant in the genes BRCA1/2 (LIBRE-1) by Berling-Ernst, A., Yahiaoui-Doktor, M., Kiechle, M., Engel, C., Lammert, J., Grill, S., Dukatz, R., Rhiem, K., Baumann, F. T., Bischoff, S. C., Erickson, N., Schmidt, T., Niederberger, U., Siniatchkin, M., Halle, M.

“…Physical activity (PA) helps prevention and aftercare of sporadic breast cancer (BC), cardiopulmonary fitness (CPF) being an age-independent predictor of…”
Get full text

The risk of endocrine interventions in carriers of a genetic predisposition for breast and gynecologic cancers: recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer by Ortmann, O., Schüler-Toprak, S., Kast, K.

“…Purpose To support doctors in counselling women with genetic predisposition for breast or gynecologic cancers on endocrine interventions. Methods Evidence on…”
Get full text

Implementation and evaluation of a nurse-led decision-coaching program for healthy breast cancer susceptibility gene (BRCA1/2) mutation carriers: a study protocol for the randomized controlled EDCP-BRCA study by Isselhard, A, Töpper, M, Berger-Höger, B, Steckelberg, A, Fischer, H, Vitinius, F, Beifus, K, Köberlein-Neu, J, Wiedemann, R, Rhiem, K, Schmutzler, R, Stock, S

“…Female BRCA mutation carriers have an increased lifetime risk for breast and ovarian cancer compared to the general population. Women who carry this mutation…”
Get full text

Corrigendum to “A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study”: [Annals of Oncology (2019), volume 30:1279-1288] by Loibl, S., Untch, M., Burchardi, N., Huober, J., Sinn, B.V., Blohmer, J.-U., Grischke, E.-M., Furlanetto, J., Tesch, H., Hanusch, C., Engels, K., Rezai, M., Jackisch, C., Schmitt, W.D., von Minckwitz, G., Thomalla, J., Kümmel, S., Rautenberg, B., Fasching, P.A., Weber, K., Rhiem, K., Denkert, C., Schneeweiss, A.

Get full text

Risk-adapted surveillance: focus on familial breast and ovarian cancer by Rhiem, K, Schmutzler, R K

“…Breast cancer surveillance programs for the general population are not adequate for the small number of women with hereditary breast and ovarian cancer…”
Get full text

Germline mutation status and therapy response in patients with triple-negative breast cancer (TNBC): Results of the GeparOcto study by Pohl, E., Schneeweiss, A., Hauke, J., Moebus, V., Furlanetto, J., Denkert, C., Fasching, P.A., Hanusch, C., Tesch, H., Weber-Lassalle, N., Müller, V., Rhiem, K., Untch, M., Luebbe, K., Lederer, B., Jackisch, C., Nekljudova, V., Schmutzler, R.K., Hahnen, E., Loibl, S.

Get full text

Impact of nab-paclitaxel dose reduction on survival of the randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy of weekly nab-paclitaxel (nP) with solvent-based paclitaxel (P) followed by anthracycline/cyclophosphamide for patients with early breast cancer (BC) by Untch, M., Jackisch, C., Schneeweiss, A., Schmatloch, S., Aktas, B., Denkert, C., Schem, C., Wiebringhaus, H., Kümmel, S., Rhiem, K., Warm, M., Fasching, P.A., Just, M., Hanusch, C., Hackmann, J., Blohmer, J.-U., Furlanetto, J., Nekljudova, V., von Minckwitz, G., Loibl, S.

Get full text

Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE) by Meyer-Wilmes, P., Huober, J., Untch, M., Blohmer, J.-U., Janni, W., Denkert, C., Klare, P., Link, T., Rhiem, K., Bayer, C., Reinisch, M., Bjelic-Radisic, V., Zahm, D.M., Hanusch, C., Solbach, C., Heinrich, G., Hartkopf, A.D., Schneeweiss, A., Fasching, P., Filmann, N., Nekljudova, V., Holtschmidt, J., Stickeler, E., Loibl, S.

“…The GENEVIEVE study, comparing neoadjuvant cabazitaxel versus paclitaxel in triple-negative breast cancer (TNBC) and luminal B/human epidermal growth factor…”
Get full text

Flächendeckende Versorgung von Familien mit erblichem Brust- und Eierstockkrebs by Rhiem, K., Schmutzler, R. K.

“…Zusammenfassung Hintergrund Vor mehr als 20 Jahren wurde das Deutsche Konsortium Familiärer Brust- und Eierstockkrebs (DK) mit Unterstützung der Deutschen…”
Get full text

Risk-reducing Surgery in Women at Risk for Familial Breast or Ovarian Cancer by Rhiem, K., Pfeifer, K., Schmutzler, R. K., Kiechle, M.

“…Abstract An estimated 5 % of breast cancers and 10 % of ovarian cancers may be due to inherited autosomal dominant breast and ovarian cancer alleles BRCA1 und…”
Get full text

Platinum Sensitivity in a BRCA1 Mutation Carrier with Advanced Breast Cancer by Rhiem, K, Wappenschmidt, B, Bosse, K, Köppler, H, Tutt, A.N, Schmutzler, R.K

“…Abstract Although BRCA1 -associated breast carcinomas are frequently detected in nodal-negative stage, they typically present with an aggressive…”
Get full text

Parametrial and rectovaginal adenocarcinoma arising from endometriosis by Ulrich, U, Rhiem, K, Kaminski, M, Wardelmann, E, Trog, D, Valter, M, Richter, O N

“…Malignant extragonadal tumors arising from endometriosis are rare. We report on two cases. A 41-year-old gravida 1, para 1 (G1P1), with adenocarcinoma of the…”
Get more information

Career and Family - Are They Compatible?: Results of a Survey of Male and Female Gynaecologists in Germany by Hancke, K, Toth, B, Igl, W, Ramsauer, B, Bühren, A, Wöckel, A, Jundt, K, Ditsch, N, Gingelmaier, A, Rhiem, K, Vetter, K, Friese, K, Kreienberg, R

“…Nowadays, most gynaecologists are female and the compatibility of job-related career and family life is an upcoming issue. The working group "Gender and…”
Get full text

The "Laparoscopic Neuro-Navigation" -- LANN: from a functional cartography of the pelvic autonomous neurosystem to a new field of laparoscopic surgery by Possover, M., Rhiem, K., Chiantera, V.

“…It is the objective of this study to etablish the technique of laparoscopic exposure of all pelvic somatic and autonomous nerves. In all our patients who…”
Get full text

Risikoadaptierte Früherkennung: Schwerpunkt: Familiärer Brust- und Eierstockkrebs by Rhiem, K., Schmutzler, R.K.

“…Zusammenfassung Die für Frauen der Allgemeinbevölkerung ohne ein familiär erhöhtes Brustkrebsrisiko zur Verfügung stehenden…”
Get full text